Mwyngil Therapeutics Announces Updates on NLRP3 Portfolio

Mwyngil Therapeutics Announces Updates on NLRP3 Portfolio February 2, 2026 / Press Releases Dover, DE – February 2nd, 2026 (PR Newswire) — Mwyngil Therapeutics, a clinical-stage biopharmaceutical company focused on immunometabolic and neuroinflammatory diseases, today announced the initiation of a Phase 1 clinical study of BT-409, a potentially best-in-class, brain-permeable NLRP3 inhibitor being developed for multiple […]